C. David James

A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma.

Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways.

Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum.

Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas.

Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism.

Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.

Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR.

MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.

Correlation of the response of recurrent malignant gliomas treated with interferon alpha with tumor interferon alpha gene content.

Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.

Altered molecular pathways in gliomas: an overview of clinically relevant issues.

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells.

mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells.

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.

Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.

PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.

Mapping the future of Neuro-Oncology.

Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.

Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.

Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.

Disabled-1 is a large common fragile site gene, inactivated in multiple cancers.

Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.

An orthotopic skull base model of malignant meningioma.

Increased expression of the glioma-associated antigen ARF4L after loss of the tumor suppressor PTEN. Laboratory investigation.

Mechanisms of chemoresistance to alkylating agents in malignant glioma.

PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.

miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.

Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.

p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts.

EGFR signals to mTOR through PKC and independently of Akt in glioma.

Stem cells for treating glioblastoma: how close to reality?

Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.

Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.

microRNAs in gliomas: small regulators of a big problem.

Immunological considerations of modern animal models of malignant primary brain tumors.

Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.

Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors.

Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.

Pleiotropic role for MYCN in medulloblastoma.

Tumor-initiating cells: an influential paradigm for xenograft research.

Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells.

Akt and autophagy cooperate to promote survival of drug-resistant glioma.

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging.

Evolution of mouse models for studying CNS cancer: a decade of progress.

Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma.

Mutational inactivation of STAG2 causes aneuploidy in human cancer.

Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.

Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

Targeted therapy for BRAFV600E malignant astrocytoma.

An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

Stimulating anti-tumor immune response: the problem of regulatory T-cells.

Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.

Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype.

An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing.

Challenges in drug delivery to tumors of the central nervous system: An overview of pharmacological and surgical considerations.